1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. c-Fms

c-Fms

CSF-1 receptor; colony stimulating factor 1 receptor; CSF-1R; CSF1R

c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. c-FMS is the cell surface receptor for IL-34 and CSF1. c-FMS has important roles in haematopoiesis, regulation of proliferation, cell survival and maturation of microglia and monocytes, as well as in controlling the overall immune response.

c-FMS is specifically expressed in osteoclasts and myelomonocytic-lineage cells, such as monocytes and macrophages, and the activation of c-FMS signaling promotes the proliferation or differentiation of these cells. It also promotes the production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL6).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-109190
    Seralutinib
    Inhibitor 99.94%
    Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.
    Seralutinib
  • HY-10204
    OSI-930
    Inhibitor 98.57%
    OSI-930 is an orally selective inhibitor of Kit, VEGFR2/KDR/Flk-1 and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα, Flt-3 and Abl. OSI-930 has antitumor activity.
    OSI-930
  • HY-18791
    c-Fms-IN-1
    Inhibitor 99.97%
    c-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM.
    c-Fms-IN-1
  • HY-13838
    PLX647
    Inhibitor 99.79%
    PLX647 is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC50s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and VEGFR2/KDR/Flk-1 (IC50s=91 and 130 nM, respectively).
    PLX647
  • HY-124526
    Chiauranib
    Inhibitor 99.28%
    Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects.
    Chiauranib
  • HY-10408
    Ki20227
    Inhibitor 99.17%
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2/KDR/Flk-1 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.
    Ki20227
  • HY-P99795
    Otilimab
    Inhibitor
    Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.
    Otilimab
  • HY-132935
    BPR1R024
    Inhibitor 99.06%
    BPR1R024 is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology.
    BPR1R024
  • HY-117244
    AZD7507
    Inhibitor 99.45%
    AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
    AZD7507
  • HY-101774
    CSF1R-IN-1
    Inhibitor 98.11%
    CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
    CSF1R-IN-1
  • HY-122906
    JTE-952
    Inhibitor 99.95%
    JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis.
    JTE-952
  • HY-153920
    Pimicotinib
    Inhibitor 99.69%
    Pimicotinib is a CSF1R inhibitor with antitumor activity.
    Pimicotinib
  • HY-P99259
    Cabiralizumab
    Inhibitor 99.59%
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research.
    Cabiralizumab
  • HY-P99452
    Axatilimab
    Inhibitor 99.59%
    Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases.
    Axatilimab
  • HY-136362
    ARRY-382
    Inhibitor 99.63%
    ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers.
    ARRY-382
  • HY-139990
    CSF1R-IN-3
    Inhibitor 98.26%
    CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity.
    CSF1R-IN-3
  • HY-126297
    c-Fms-IN-10
    Inhibitor 98.63%
    c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 has anti-tumor activity.
    c-Fms-IN-10
  • HY-161025
    SYHA1813
    Inhibitor 99.46%
    SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM.
    SYHA1813
  • HY-147615
    CSF1R-IN-12
    98.75%
    CSF1R-IN-12 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1).
    CSF1R-IN-12
  • HY-112451
    cFMS Receptor Inhibitor II
    Inhibitor 99.88%
    cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. CSF-1 is a cytokine.
    cFMS Receptor Inhibitor II
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity